Use of the GenoType MTBDRplus for early diagnosis of multidrug-resistant tuberculosis

Authors

  • O. M. Raznatovska Zaporizhzhia State Medical University,
  • R. M. Yasinskyi Zaporizhzhia State Medical University,
  • O. V. Konakova Zaporizhzhia State Medical University,
  • Jean-Luc Berland Fondation Mérieux, Emerging Pathogens Laboratory (EPL), France,
  • Marie Gauhier Fondation Mérieux, Emerging Pathogens Laboratory (EPL), France,

DOI:

https://doi.org/10.14739/2310-1210.2017.2.95741

Keywords:

diagnosis, GenoType MTBDRplus, MDR TB

Abstract

The type of diagnostics methods and their duration, loss of time for the appointment of the optimal treatment are the major categories of factors that influence on multidrug resistant tuberculosis treatment effectiveness. Problem of multidrug resistant tuberculosis and improving of its laboratory diagnosis is very important in Ukraine. Inadequate and ineffective treatment is applied in cases of delayed diagnostic of multidrug resistant tuberculosis in patient. It causes further spread of drug-resistant tuberculosis and increase of mycobacterium tuberculosis drug resistance to anti-tuberculosis drugs. Therefore, rapid diagnostics of multidrug resistant tuberculosis is a requirement for timely and correct treatment strategy, and one of the urgent problems of modern phthisiology.

The aim of this review was to evaluate the GenoType MTBDRplus for early diagnosis of multidrug-resistant tuberculosis diagnostic in Ukraine.

Conclusions. Use of the GenoType MTBDRplus (2.0) assay for rapid multidrug resistant tuberculosis detection in Ukraine is important. With Genotype MTBDRplus test TB Complex identification and resistance detection to INH and RMP is completed in 8 hours compared to 25 days in Bactec MGIT 960 System and three months on solid LG medium. Pulmonary specimens (sputum, bronchoalveolar lavage, bronchoscopic aspirate), as well as clinical specimens from extrapulmonary sites (pleural fluid, lymph node biopsy, ascitic fluid, cerebrospinal fluid) can be used. Smear-positive patients, as well smear-negative and pulmonary cases as well extra-pulmonary, would be to benefit from using the revised version 2.0 of MTBDRplus. The sensitivity of this method is 95 to 97 % and the specificity – up to 90.7 %. It is recommended for detection of MDR TB in contact persons, for screening of multi-resistant tuberculosis patients and for detection of multi-resistant tuberculosis in TB patients with treatment failure, for determination of genotype of Mycobacterium tuberculosis in the region. Qualified bacteriologic diagnostics has the potential to interrupt the transmission chain of resistant M. tuberculosis.

References

Ohliad sytuatsii z tuberkulozu [Overview of the situation of tuberculosis]. Proceedings of the 46 th World Conference on Lung Health. Retrieved from: http://stbcu.com.ua/2015/sytuatsia/. [in Ukrainian].

Feshchenko, Yu. I., & Melnyk, V. M. (2013) Orhanizatsiia kontroliu za khimiorezystentnym tuberkulozom Vyrobnyche vydannia [Company for control of MDR tuberculosis. Production edition]. Kyiv: Zdorovia [in Ukrainian].

(2015). Tuberkuloz v Ukraini: analitychno-statystychnyi dovidnyk [Tuberculosis in Ukraine: analytical and statistical]. Kyiv: Blank-Pres. Retrieved from http://www.slideshare.net/Ukraine_CDC/2014-52881494. [in Ukrainian].

Filatova, O. V., & Boyko M. G. (2013). Rol henetychnykh doslidzhen v likuvanni tuberkulozu [Role of Genetic Researches in Tuberculosis Treatment]. Visnyk problem biolohii i medytsyny, 1, 2(99), 221–223. [in Ukrainian].

Yerokhin, V. V. & Chernousova, L. N. (2011). Znachenie molekulyarno-geneticheskikh issledovanij v modernizacii ftiziatrii [Significance of molecular genetics tests for modernization of phyziatry]. Ftiziatriya i pul´monologiya, 2(2), 52–53. [in Ukrainian].

Raznatovskaya, E. N., Khudyakov, G. V., & Gricova N. A. (2016). Molekulyarno-geneticheskie metody diagnostiki i ikh ispol´zovanie vo ftiziatrii [Molecular genetic diagnostic methods and their use in TB]. Suchasni medychni tekhnolohii, 2, 63–71. [in Ukrainian].

Zhurylo, O. A., Barbova, A. I., Hlushkevych, T. H., & Tretiakova, L. V. (2012). Standarty bakteriolohichnoi diahnostyky tuberkulozu v laboratoriiakh protytuberkuloznykh zakladiv Ukrainy: navchalnyi posibnyk dlia fakhivtsiv bakteriolohichnykh laboratorii zakladiv protytuberkuloznoi sluzhby Ukrainy [Standards bacteriological diagnosis of tuberculosis in the laboratory TB facilities Ukraine: a manual for professionals bacteriological laboratories TB service institutions of Ukraine]. Kyiv [in Ukrainian].

Nakaz MOZ Ukrainy «Ukraina. MOZ. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy doroslym “Tuberkuloz”» vid 04.09.2014 r. №620 [Order of the Ministry of Health of Ukraine Unified clinical protocols of primary, secondary (specialized) and tertiary (highly specialized) medical care for adults "Tuberculosis" from Semptember, 4, 2014, №620]. [in Ukrainian].

Zhurylo, O. A., Barbova, A. I.,. Cherenko, S. O., et al. (2013). Alhorytm diahnostyky khimiorezystentnoho tuberkulozu z kompleksnym vykorystanniam heno- ta fenotypichnykh metodiv v bakteriolohichnykh laboratoriiakh protytuberkuloznykh zakladiv Ukrainy : metodychni rekomendatsii [Algorithm for diagnosis of tuberculosis himiorezystentnoho integrated use of geno - and phenotypic methods in bacteriological laboratories TB facilities Ukraine: guidelines]. Kyiv. [in Ukrainian].

Melnyk, V. M., Matusevych, V. H., Novozhylova, I. O., Yukhymets, V. O., Lynnyk, M. I., Antonenko, L. F. et al. (2014). Orhanizatsiia vyiavlennia ta likuvannia khvorykh na khimiorezystentnyi tuberkuloz [Organization detection and treatment of tuberculosis himiorezystentnyy]. Kyiv. [in Ukrainian].

Raznatovskaia, Ye. N., Mykhailova, A. A., & Kostenko, I. A. (2015). E´ffektivnost´ Genexpert MTB/RIF u bol´nykh s novymi sluchayami i recidivami tuberkuleza legkikh. [Efficiency of Genexpert MTB/RIF in patients with newly diagnosed and reccurent pulmonary tuberculosis]. Aktual´naya infektologiya, 2, 55–57. [in Ukrainian].

Nosova, E. Yu., Krasnova, M. A., Galkina, K. Yu., Makarova, M. V., Litvinov, V. I., & Moroz, A. M. (2013). Sravnitel´naya ocenka e´ffektivnosti molekulyarnykh test sistem «TB BIOChIP», «Xpert MTB/RIF» i «GenoType MTBDRplus» dlya bystrogo opredeleniya mutacij, otvetstvennykh za lekarstvennuyu ustojchivost´ Mycobacterium tuberculosis complex (v respiratornom materiale pacientov moskovskogo regiona) [Comparing performance of "TB-Biochip", "Xpert® MTB/RIF" and "GenoType MTBDRplus" assays for fast identification of mutations in the Mycobacterium tuberculosis complex in sputum from tb patients]. Molekulyarnaya biologiya, 47(2), 267–274. [in Russian]. doi: 10.7868/S0026898413010102.

Cherenko, S. O., Varytska, N. A., Barbova, A. I., & Trofimova, P. S. (2014). Kontynhenty khvorykh z hrup vysokoho ryzyku shchodo multyrezystentnoho tuberkulozu Rif+ za rezultatamy obstezhennia khvorykh za dopomohoiu Genexpert MTB/RIF [Contingent of patients at high risk of multidrug-ressistant tuberculosis Rif + from the results of the survey of patients using GenExpert MTB/RIF]. Tuberkuloz, lehenevi khvoroby, VIL-infektsiia, 4(19), 29–33. [in Ukrainian].

Barbova, A. I., Zhurylo, O. A., Zherebko, N. M., & Chaika, A. O. (2014). Poriadok vykorystannia molekuliarno-henetychnykh metodiv u laboratoriiakh z diahnostyky tuberkulozu v Ukraini [The procedure for using molecular genetic techniques in the laboratory diagnosis of tuberculosis in Ukraine]. Kyiv. [in Ukrainian].

Ignat´eva, O. A. (2015). Lekarstvennaya ustojchivost´ shtam mov M. tuberculosis i optimizaciya diagnosticheskikh algoritmov na primere Samarskoj oblasti (Dis…kand. biol. nauk). [Drug resistance of M. tuberculosis strains and optimization of diagnostic algorithms as an example of the Samara region Dr. biol. sci. diss.]. Samara [in Russian].

Balabanova, Ja. M., Drobnievskij, F., Fedorin, I. M., Malomanova, N. A., & Ignat'eva, O. A. (2011). Optimizatsiya laboratornoj diagnostiki tuberkuleza s ispol´zovaniem sovremennykh bakteriologicheskikh i molekulyarno-geneticheskikh metodov [Optimization of the laboratory diagnosis of TB using modern bacteriology and molecular genetic methods]. Problemy tuberkuleza i boleznej legkikh, 2, 36–43. [in Russian].

Nikolaevskij, V. V., Balabanova, Ya. M., Mironova, S. A., Fedorin, I. M., Malomanova, N. A., Ignat'eva, O. A., et al. (2010). Chuvstvitel´nost´ i specifichnost´ molekulyarno-geneticheskoj test-sistemy Hain MTBDRplus dlya e´kspress- diagnostiki lekarstvennoj chuvstvitel´nosti mikobakterij tuberkuleza na materiale mokroty [The sensitivity and specificity of molecular genetic test systems Hain MTBDRplus for rapid diagnosis of Mycobacterium tuberculosis drug susceptibility testing from the sputum]. Problemy tuberkuleza i boleznej legkikh, 4, 28–34. [in Russian].

Eliseev, P. I., Tarasova I. V., Gorina G. P., et al. (2010). Sravnitel´naya kharakteristika metodov Genotype MTBDRplus i absolyutnykh koncentracij na srede Levenshtejyna-Yensena pri opredelenii lekarstvennoj chuvstvitel´nosti vozbuditelya tuberkuleza [Comparative characteristics of methods Genotype MTBDRplus and absolute standart on Lowenstein-Jensen medium in determining the drug sensitivity of tuberculosis pathogen]. Sovershenstvovanie medicinskoj pomoschi bol´nym tuberkulezom. Proceedings of the All-Russian Scientific and Practical Conference. Saint Petersburg [in Russian].

Adambekova, A. D. (2013). Kharakteristika mutacyj gena rpoB, vyzyvayuschego razvitie rezistentnosti k rifampicinu na territorii Kyrgyzskoj respubliki [Characteristic of gene mutations rpoB, causing the development of resistance to rifampicin in the Kyrgyz republic]. Vestnik Kyrgyzsko-Rossijskogo Slavyanskogo Universiteta im. B. El'cina, 11(13), 22–24. [in Kyrgyzstan].

Eliseyev, P. I., Tarasova, I. V., Nikishova, E. I., & Maryandyshev, A. O. (2013). Rezul´taty primeneniya metoda Genotype MTDRSL dlya opredeleniya lekarstvennoj chuvstvitel´nosti vozbuditelya tuberkuleza k e´tambutolu, ofloksacinu, kanamicinu, i kapreomicinu v Arkhangel´skoj oblasti [Results of using the genotype MTBDRSL test to detect drug susceptibility in tuberculosis pathogen to ethambutol, ofloxacin, canamycin, and capreomycin in the arkhangelsk region]. Tuberkulez i bolezni legkikh, 1, 32–36. [in Russian].

World Health Organization. Global TB database. WHO, Geneva. Retrieved from https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=UA&LAN=RU&outtype=html.

(2015).World Health Organization. Tuberculosis surveillance and monitoring in Europe 2015. WHO, Geneva Retrieved from http://ecdc.europa.eu/en/publications/Publications/tuberculosis-surveillance-monitoring-Europe-2014.pdf.

Bastard, M., Sanchez-Padilla, E., Hewison, C., Hayrapetyan, A., Khurkhumal, S., Varaine, F., & Bonnet, M. (2015). Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia. J Infect Dis, 211, 1607. doi: 10.1093/infdis/jiu551.

(2016). World Health Organization. Global Tuberculosis Report 2014. WHO, Geneva Retrieved from http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1.

(2012) World Health Organization. Global tuberculosis report 2012. Sourse: Global tuberculosis database, WHO.

(2012) World Health Organization. Global tuberculosis report 2012. WHO document WHO/HTM/TB/2012.6. Geneva.

(2016) World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line antituberculosis drugs: Policy guidance. WHO, Geneva. Retrieved from http://www.who.int/tb/WHOPolicyStatementSLLPA.pdf?ua=1 (Accessed on May 23, 2016).

Centers for Disease Control and Prevention. Tuberculosis. Retrieved from http://www.cdc.gov/tb/topic/laboratory/ (Accessed on June 16, 2016).

(2012) Centers for Disease Control and Prevention. Reference Laboratory Division of TB Elimination Laboratory User Guide for U.S. Public Health Laboratories: Molecular Detection of Drug Resistance (MDDR) in Mycobacterium tuberculosis Complex by DNA Sequencing (Version 2.0), June 2012. Retrieved from http://www.cdc.gov/tb/topic/laboratory/mddrusersguide.pdf (Accessed on June 16, 2016).

(2013) World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children, Policy update. WHO, Geneva. Retrieved from http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335_eng.pdf?ua=1 (Accessed on May 17, 2016).

Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014). Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev., 1, 1–166. doi: 10.1002/14651858.CD009593.pub3.

Jacobson, K. R., Theron, D., Kendall, E. A., Franke, M. F., Barnard, M., van Helden, R. M., et al. (2013). Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis, 56, 503. doi: 10.1093/cid/cis920.

Crudu, V., Stratan, E., Romanenco, E., Allerheiligen, V., Hillemann, A., & Moraru, N. (2012). First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as RMP and INH resistances. J Clin Microbiol, 50(4), 1264–1269. doi: 10. 1128/JCM. 05903–11.

Kipiani, M., Mirtskhulava, V., Tukvadze, N., Magi, M., Blumberg, H. M., & Kempker, R. R. (2014). Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis. Clin Infect Dis, 59, 1559–66. doi: 10.1093/cid/ciu631.

Yadav, R. N., Singh, B. K., Sharma, S. K., Sharma, R., Soneja, M., Sreenivas, V., et al. (2013). Comparative Evaluation of GenoType MTBDRplus Line Probe Assay with Solid Culture Method in Early Diagnosis of Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Centre in India. PLOS ONE, 8(9), e72036. doi: 10.1371/journal.pone.0072036.

Biadglegne, F., Tessema, B., Rodloff, A. C., & Sack, U. (2013). Magnitude of Gene Mutations Conferring Drug Resistance in Mycobacterium Tuberculosis Isolates from Lymph Node Aspirates in Ethiopia. Int. J. Med. Sci, 10, 1589–1594. doi: 10.7150/ijms.6806.

Theron, G., Peter, J., Richardson, M., Barnard, M., Donegan, S., Warren, R., et al. (2014). The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev, 10, CD010705. doi: 10.1002/14651858.CD010705.pub2.

Downloads

How to Cite

1.
Raznatovska OM, Yasinskyi RM, Konakova OV, Berland J-L, Gauhier M. Use of the GenoType MTBDRplus for early diagnosis of multidrug-resistant tuberculosis. Zaporozhye Medical Journal [Internet]. 2017Mar.14 [cited 2024Nov.22];19(2). Available from: http://zmj.zsmu.edu.ua/article/view/95741

Issue

No. 2 (2017): Zaporozhye medical journal

Section

Review

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)